146 related articles for article (PubMed ID: 37652494)
1. Predictors of Outcomes in Patients With Clinically Lymph Node Positive Prostate Cancer After Definitive Radiotherapy.
Kim TH; Kim DY; Kim JS
In Vivo; 2023; 37(5):2365-2370. PubMed ID: 37652494
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer.
Tsuchida K; Inaba K; Kashihara T; Murakami N; Okuma K; Takahashi K; Igaki H; Nakayama Y; Maejima A; Shinoda Y; Matsui Y; Komiyama M; Fujimoto H; Ito Y; Sumi M; Nakano T; Itami J
Cancer Med; 2020 Sep; 9(18):6629-6637. PubMed ID: 32750234
[TBL] [Abstract][Full Text] [Related]
3. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
[TBL] [Abstract][Full Text] [Related]
4. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
Bryant AK; Kader AK; McKay RR; Einck JP; Mell LK; Mundt AJ; Kane CJ; Efstathiou JA; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1188-1193. PubMed ID: 29891203
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.
Ventimiglia E; Seisen T; Abdollah F; Briganti A; Fonteyne V; James N; Roach M; Thalmann GN; Touijer K; Chen RC; Cheng L
Eur Urol Oncol; 2019 May; 2(3):294-301. PubMed ID: 31200844
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy.
Chen H; Qu M; Shi H; Dong Z; Wang Y; Gao X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4925-4932. PubMed ID: 36308526
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Amit U; Lawrence YR; Weiss I; Symon Z
Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
[TBL] [Abstract][Full Text] [Related]
10. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE
PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
13. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
14. Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a?
Chopade P; Maitre P; David S; Panigrahi G; Singh P; Phurailatpam R; Murthy V
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):711-717. PubMed ID: 35870708
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Kishan AU; Sun Y; Hartman H; Pisansky TM; Bolla M; Neven A; Steigler A; Denham JW; Feng FY; Zapatero A; Armstrong JG; Nabid A; Carrier N; Souhami L; Dunne MT; Efstathiou JA; Sandler HM; Guerrero A; Joseph D; Maingon P; de Reijke TM; Maldonado X; Ma TM; Romero T; Wang X; Rettig MB; Reiter RE; Zaorsky NG; Steinberg ML; Nickols NG; Jia AY; Garcia JA; Spratt DE;
Lancet Oncol; 2022 Feb; 23(2):304-316. PubMed ID: 35051385
[TBL] [Abstract][Full Text] [Related]
16. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
17. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
18. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
19. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
[TBL] [Abstract][Full Text] [Related]
20. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
